Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Calif First National (CFNB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 177,330
  • Shares Outstanding, K 10,280
  • Annual Sales, $ 36,690 K
  • Annual Income, $ 11,120 K
  • 36-Month Beta 0.18
  • Price/Sales 4.64
  • Price/Cash Flow 16.19
  • Price/Book 0.90
  • Price/Earnings ttm 15.77
  • Earnings Per Share ttm 0.22
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 09/21/18
  • Annual Dividend & Yield 0.48 (2.78%)
  • Most Recent Dividend 0.480 on 12/08/17
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.7000 unch
on 09/21/18
17.9400 -6.91%
on 08/23/18
-0.8000 (-4.57%)
since 08/21/18
3-Month
15.7500 +6.03%
on 07/17/18
17.9400 -6.91%
on 08/23/18
+0.9000 (+5.70%)
since 06/21/18
52-Week
12.5500 +33.07%
on 11/10/17
18.7000 -10.70%
on 10/09/17
+0.4500 (+2.77%)
since 09/21/17

Most Recent Stories

More News
Gene Panel Market to Soar 19.2% CAGR to 2023, Led by North America

ReportsandReports added gene panels market research, it includes Illumina, Inc. (US), BGI (China), Agilent Technologies (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Inc. (US), Novogene Corporation...

A : 70.81 (-0.45%)
ILMN : 358.46 (+0.60%)
CFNB : 16.7000 (-3.19%)
Global Gene Panel Market Report 2018-2023 - Expected to Reach $2.95 Billion Due to Increasing Prevalence of Chronic Diseases

The "Gene Panel Market by Product & Service, Technique (Amplicon, Hybridization), Design (Predesign, Custom), App (Cancer, Congenital Disease, Pharmacogenetics) & End User (Hospital, Research Center, Pharmaceutical...

CFNB : 16.7000 (-3.19%)
Swift Biosciences Launches Accel-Amplicon Plus Cancer Panels for Precision Medicine Initiatives

New targeted sequencing workflow combines pre-validated content with easy customization and new analysis tools to accelerate variant discovery and screening

CFNB : 16.7000 (-3.19%)
Analysis: Positioning to Benefit within Lithium and California First National - Research Highlights Growth, Revenue, and Consolidated Results

NEW YORK, NY / ACCESSWIRE / March 9, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Lithium Corporation (OTCQB: LTUM) and California First National Bancorp...

LTUM : 0.2100 (+16.67%)
CFNB : 16.7000 (-3.19%)
The global targeted DNA/RNA sequencing market is expected to reach USD 15.9 billion by 2025

Targeted DNA/RNA Sequencing Market Analysis By Technology (NGS, Exome Sequencing Seq., Enrichment Seq., Amplicon Seq., Sanger Seq.), By Workflow, By Application, By Type, By End-use, And Segment Forecasts,...

CFNB : 16.7000 (-3.19%)
Toyota Signs Licensing Agreement with Kazusa DNA Research Institute, Eurofins Genomics, and GeneBay for GRAS-Di DNA Analysis Technology

Toyota Motor Corporation (Toyota) announces that it has signed an agreement with Kazusa DNA Research Institute, Eurofins Genomics K.K., and GeneBay Inc. on October 30 to license Toyota's unique GRAS-Di(1)...

CFNB : 16.7000 (-3.19%)
TM : 124.58 (-0.30%)
CFNB First Quarter 2018 Earnings Up 17% Despite Decline in Assets

California First National Bancorp (NASDAQ: CFNB; "CalFirst Bancorp" or the "Company") net earnings of $2.3 million for the first quarter ended September 30, 2017 are up 17.2% from $1.96 million...

CFNB : 16.7000 (-3.19%)
California First National Bancorp Announces Voluntary Plans for NASDAQ Delisting and SEC Deregistration of Common Stock and Filing of Application with the OTCQX Market

California First National Bancorp (NASDAQ: CFNB, the "Company") today announced that its Board of Directors approved the Company undertaking to voluntarily delist its common stock from the...

CFNB : 16.7000 (-3.19%)
GENEWIZ Launches Expanded Next Generation Sequencing Services Including Quick-Turn Amplicon-EZ and Long-Read Amplicon Sequencing at ASHG

ASHG17, Booth #323 -- Leading global genomics service provider, GENEWIZ, launches CLIA Sanger sequencing and new NGS amplicon sequencing, at booth #323 during The American Society of Human Genomics (ASHG)...

CFNB : 16.7000 (-3.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade CFNB with:

Key Turning Points

2nd Resistance Point 17.2500
1st Resistance Point 17.2500
Last Price 16.7000
1st Support Level 17.2500
2nd Support Level 17.2500

See More

52-Week High 18.7000
Last Price 16.7000
Fibonacci 61.8% 16.3507
Fibonacci 50% 15.6250
Fibonacci 38.2% 14.8993
52-Week Low 12.5500

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar